Intelligence Driven Advisers’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$793K Buy
661
+185
+39% +$189K 0.13% 59
2026
Q1
$438K Sell
476
-10
-2% -$10.1K 0.08% 70
2025
Q4
$522K Sell
486
-15
-3% -$14.3K 0.07% 71
2025
Q3
$382K Sell
501
-49
-9% -$36.5K 0.05% 77
2025
Q2
$429K Sell
550
-552
-50% -$429K 0.06% 71
2025
Q1
$910K Sell
1,102
-669
-38% -$557K 0.18% 44
2024
Q4
$1.37M Sell
1,771
-22
-1% -$18.2K 0.26% 35
2024
Q3
$1.59M Buy
1,793
+594
+50% +$534K 0.23% 32
2024
Q2
$1.09M Sell
1,199
-51
-4% -$40.8K 0.15% 43
2024
Q1
$972K Sell
1,250
-50
-4% -$35.6K 0.14% 39
2023
Q4
$839K Buy
1,300
+373
+40% +$218K 0.14% 39
2023
Q3
$493K Buy
927
+138
+17% +$71.1K 0.09% 53
2023
Q2
$365K Buy
789
+134
+20% +$56.2K 0.06% 63
2023
Q1
$237K Sell
655
-364
-36% -$123K 0.04% 80
2022
Q4
$370K Buy
1,019
+5
+0.5% +$1.77K 0.07% 65
2022
Q3
$338K Buy
1,014
+369
+57% +$117K 0.07% 83
2022
Q2
$213K Buy
+645
New +$194K 0.04% 95

Other funds holding LLY

Intelligence Driven Advisers's LLY Position: Q2 2026 in Review

Intelligence Driven Advisers increased its Eli Lilly (LLY) stake by 39% in Q2 2026, buying an estimated $189K and bringing the position to 661 shares worth $793K. The position accounts for 0.13% of the portfolio, ranked #59.

Intelligence Driven Advisers first reported a position in LLY in Q2 2022 and has held it in 17 quarters since. The position peaked at $1.59M in Q3 2024. 4,618 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Intelligence Driven Advisers held 661 shares of Eli Lilly worth $793K as of Q2 2026.
  • Intelligence Driven Advisers bought 185 Eli Lilly shares in Q2 2026, an estimated $189K.
  • Eli Lilly made up 0.13% of Intelligence Driven Advisers's portfolio in Q2 2026, its #59 holding.
  • Intelligence Driven Advisers first reported a position in Eli Lilly in Q2 2022 and has held it in 17 quarters since.
  • Intelligence Driven Advisers's Eli Lilly position peaked at $1.59M in Q3 2024.
  • 4,618 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Intelligence Driven Advisers's 13F filing for Q2 2026, filed 6 Aug 2026.